glp-1 drugs and pancreatitis Suspected drug-induced was rare but more common in patients taking agonists than sulfonylureas, a recent analysis of a VA database finds Concerns Raised Over Pancreatitis Risk

Im not dismissing any of it

doi: 10.1371/journal.pone.0100777

Koob, G

Mazdutide (IBI362): The Next-Generation Dual GLP-1/Glucagon Agonist for Obesity and Metabolic Health Abstract Mazdutide (IBI362) is an emerging dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics for obesity and metabolic diseases

Ste 305, Newark, DE 19713 Important Regulatory and Industry Factors to Consider Anyone researching weight loss pills for 2026 should be aware of broader regulatory and industry developments that may affect availability and access

Nevertheless, translating these experimental technologies into safe, effective, and commercially viable products requires extensive clinical trials to establish pharmacokinetics, bioavailability, efficacy, and safety profiles